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Dear Colleagues,
This year’s Children’s Mercy Hospital’s Cancer Center Annual Report focuses upon
Ewing’s sarcoma, one of two bone tumors that predominate in children. Typically,
these tumors account for five to six percent of all childhood malignancies. However,
among our adolescent population these tumors are twice as common constituting
a greater proportion (eight to 11 percent) of the cancers. These tumors are
predominantly affecting a group of individuals who we in Pediatric Oncology consider
a high risk and forgotten population.
First, they are in a phase of transition from childhood to adulthood. Many issues
are impacting their lives at this age and the quandary of who they are and who they
will be as adults is so important at this age. Equally strong an issue is their feeling
of invincibility at this age. For these and a myriad of other reasons, there is often a
longer period of time between symptom onset and the parent’s awareness and thus
their cancer’s diagnosis. These delays in diagnosis, as well as delays in revealing
evolving complications during therapy, increase their risk for a poor outcome.
Teens, as we all know, are neither children nor adults, but a group with unique
challenges and needs that must be attended to in order to maximize their chance of
cure and survival.
By this time in their life, these young adults are questioning whether they wish to
be seen by pediatricians or by adult specializing medical practitioners. Thus, we
see among this age group an increasing proportion of newly diagnosed individuals
migrating towards the adult oncology specialists. Normally, we would say there is
nothing wrong with this, just so they see somebody trained in the care of people
with cancer. But, interestingly, recent analyses in the medical literature have now
repeatedly shown that adolescents and young adults actually have a significantly
better chance of cure when treated with regimens originating in the pediatric cancer
clinical trials compared to therapies utilized in adults with cancer. This is also the
case in Ewing’s sarcoma patients where there has been seen a full 15-20 percent
better survival at pediatric institutions than adult institutions. While an array of
reasons may be present for this finding, it is felt to be due primarily to the more
aggressive approach to therapy, which in addition to more intensive chemotherapy
and doses, utilizes an integrated multidisciplinary team not always available in
other settings. A pediatric oncology team approaches patients from the standpoint
that they are otherwise healthy individuals with the ability to tolerate an aggressive
approach, whereas an adult oncologist primarily takes care of older individuals with
cancer who normally have a limited ability to tolerate aggressive chemotherapy. This
limitation is generalized to the adolescents and young adults who in reality actually
can tolerate the more intense regimens of pediatric oncology.
Alan S. Gamis, MD, MPH
Director of Oncology
Chair, CMH Cancer Care
Committee

Finally, they are a part of a forgotten age group in the realm of clinical research.
The patients between the ages of 15 and 35 years have the lowest participation
rates in clinical trials and have had the smallest improvement in cure rates over
the past several decades. Fortunately, attention is now being brought to this
group of patients and the clinical trials of the National Cancer Institute’s Children’s
Oncology Group are now targeting and including patients up to the age of 30 years
and occasionally higher. Children’s Mercy Hospital, as one of the larger children’s
cancer centers in the COG, is an active participant in these clinical trials with
approximately 100 different clinical trials available for children and adolescents
up to the age of 21 years diagnosed with cancer. Not only is Children’s Mercy a
participant in this effort but the members of the cancer program are also leaders in
the fight against childhood cancer via leadership of many of these national clinical
trials and the participation in the expert panels that oversee the research of the
COG. A child diagnosed and treated with Ewing’s Sarcoma at Children’s Mercy
Hospital thus benefits from this cutting edge activity. They, as well, are overseen by
a multidisciplinary team of caregivers which provides a comprehensive approach to
adolescents’ cancer therapy as well as their future and their family’s needs. I am
very happy to be able to share with you the work of our team through the focus of
this year’s Annual Report upon Ewing’s sarcoma.

Dear Colleagues,
Again this year, we are pleased to share with you the Cancer Care Annual
Report from Children’s Mercy Hospitals and Clinics in Kansas City. All of
us at Children’s Mercy are extremely proud of our nationally-recognized
Hematology/Oncology team and the work they do in providing a bright
future for hundreds of children with cancer each year.
The title of this year’s report, “Transitions,” focuses on working with
teen-age patients as they transition from childhood to adulthood, and
the special needs of adolescent patients with Ewing’s sarcoma. But
“transitions” also could apply to everything we do here at Children’s
Mercy. We continue to grow in facilities, programs and research as the
needs of the pediatric and adolescent population in our region continue
to grow and change.
I hope you will take a few minutes to review this year’s annual report,
which is aimed at keeping community physicians and others informed of
our progress regarding the diagnosis and treatment of childhood cancer.
It’s essential that this treatment involves the support of the entire family,
and Children’s Mercy is nationally known for the unique, family-centered
environment which we provide to meet each child and family’s individual
needs through innovative, creative venues.

Randall L. O’Donnell, PhD
President & CEO

Our goal is to provide care in a
		 family-centered care environment...

Division of Hematology/Oncology
The Division of Hematology/Oncology
at Children’s Mercy Hospitals and
Clinics is dedicated to providing
comprehensive care to children with
cancer and blood disorders. Our goal
is to provide this care in a familycentered care environment in an effort
to promote health and well being. The
division is divided into two sections: the
Section of Oncology and the Section
of Hematology. The Division Chair
is Gerald Woods, MD. The Division
Manager is Sue Stamm, RN, MHA,
CPNP.

The Section of OncologySection Chief-Alan Gamis, MD
The Bone Marrow Transplant
Service- Director-Charles Peters,
MD: provides hematopoieticstem cell
rescue to patients receiving myelosuppressive or ablative therapy which
requires stem cell rescue. Stem cell
rescue is accomplished by utilizing
umbilical stem cells, matched-related
donor cells, and matched-unrelated
donor cells. Children’s Mercy Hospital
participates in the National Marrow
Donor Program, the International
Blood and Marrow Transplant Registry.
Research protocols run by the
Pediatric Blood and Marrow Transplant
Consortium, National Institutes of

Health, and the Children’s Oncology
Group are also available for qualifying
patients.
The Oncology Service-DirectorAlan Gamis, MD: dedicated to the
treatment of malignant disorders. In
2004 this service diagnosed 145 new

cases of cancer or other reportable
diseases. The Oncology Service treats
patients in accordance with clinical
trials under the guidance of the
Children’s Oncology Group.

The Section of HematologySection Chief-Gerald Woods,
MD
The Sickle Cell Disease ServiceDirector-Gerald Woods, MD:
offers specialized care for the unique
diagnostic and treatment needs of
children and adolescents diagnosed
with sickle cell disease. These patients
and families are confronted with
episodes of acute pain, life limiting
chronic pain, and other long term
sequelae related to this devastating
disease.
The Regional Hemophilia CenterDirector-Brian Wicklund, MD:
supports seven sites in a five-state
region to provide comprehensive
treatment for both adult and pediatric
patients with bleeding disorders. In
addition, this service supports the
diagnosis and treatment of coagulation
and/or thrombosis disorders.
Children’s Mercy Cancer Care
Committee
The Children’s Mercy Hospital Cancer
Care Committee is a standing medical
staff committee that provides oversight
of the oncology services. The
committee is chaired by the section
chief for the Section of Oncology and
has both physician and non-physician
representation (see member listing).
It is comprised of a multidisciplinary
team of physicians, staff, and other
discipline from across the institution.
The committee meets quarterly and
reviews patient acuity, program services
and quality initiatives, and determines
quality improvement needs and
opportunities related to pediatric cancer
prevention, diagnosis, treatment, and
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outreach. The committee functions in
accordance with the American College
of Surgeons’ accreditation standards.
Pediatric Hematology/Oncology
Fellowship Program
The fellowship program at Children’s
Mercy Hospital trains the future
pediatric hematology/oncology
specialists. This program requires
intense clinical and research training for
a minimum of three years. Each fellow
at Children’s Mercy Hospital enters the
fellowship program as a fully trained
pediatrician. The first 18 months are
dedicated primarily to clinical care and
becoming familiar with procedures and
standards of practice. The subsequent
18 months are dedicated heavily to
clinical and laboratory research. The
Division of Hematology/Oncology at
Children’s Mercy Hospital currently
supports three fellowship positions.

the patient’s history, physical findings at
diagnosis, laboratory values, radiology
exams, surgical interventions, and
pathological findings. This diagnostic
review is followed by a thorough
review of the potential treatment
options, current therapy available,
response to therapy, if applicable,
and anticipated prognosis. Medical
specialists from oncology, surgery,
pathology, radiology, radiation oncology,
neurosurgery, orthopedic surgery,
endocrine, psychology, and dentistry
are represented. In addition, nonphysician representatives include:
advanced practice nursing, physician’s
assistants, hospital management/
administration, social workers, child life
specialists, chaplain, dieticians, and
staff nurses. These cancer conferences
offer CME credits and are conducted in
accordance with the American College
of Surgeons’ accreditation standards.

The Children’s Mercy Cancer
Center Cancer Care Conferences
The Children’s Mercy Cancer Center
Cancer Care Conferences provide
opportunities for a multidisciplinary
discussion regarding newly diagnosed
patients, recurrent/relapsed patients,
and unusual pediatric cancer cases.
The conference consists of a review of

Case Management
Each physician within the Hematology/
Oncology Division works in close
collaboration with an advanced practice
nurse, physician assistant or nurse in
expanded role to comprise a primary
team for the children and family to
identify. These teams coordinate every
aspect of the patient’s care throughout

treatment and during post-treatment
follow-up. The case manager is the
primary contact person for the patient
and the family.

Psychosocial Services
Parent-to-Parent Program: designed
to connect parents who have been
through the cancer experience with
parents of a newly diagnosed child
with cancer. In addition, this program
offers support groups on a weekly basis
facilitated by parent volunteers under
the oversight of a social worker.
Social Work and Community
Services: there are five full-time social
workers dedicated to the Division of
Hematology/Oncology. The primary
focus of this team is to assist the
patient and the family in understanding
the impact the diagnosis of cancer will
have on their family dynamics and life
style.
Bereavement Support Group/
Program: this program is offered to
parents who have experienced the loss
of a child. The program includes staff
contacts to parents/family members
during significant events such as
birthdays, anniversary date for the
death of the child, an annual memorial
service, and the composition of a
memory book.
Child Psychologist: a full-time
psychologist provides support to the
patient, parents, and siblings of those
diagnosed with childhood cancer.
Chaplaincy: a full-time chaplain
supports the spiritual needs of the
patients and their families. There is a
chaplain available 24 hours a day.

The Children’s Mercy Cancer Center’s
Holiday Hero

Child Life Therapist/Music
Therapist: two full-time Child Life
therapists, one full-time Child Life
assistant and one part-time music
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A team of division members works to build
				
strong connections among the hospital,
		parents/child, and each child’s school.
therapist work with patients, parents,
and siblings to aid in the adjustment
and ongoing support associated with
diagnosis and treatment of childhood
cancer.

Nutrition/Pharmacy Services

In addition to providing support for
current patients, members of the
division also provide preventive
education/outreach regarding topics
such as smoking cessation and sun
exposure. These programs are tailored
to the appropriate age group being
spoken to.

Nutrition: two full-time and one parttime registered dieticians support the
nutrition needs of the patient/family. In
addition, there is a nutrition tech that
adds support to the team.
Pharmacy: two full-time pharmacists
and one full time technician support
the operations of a satellite pharmacy
Monday-Friday, 7:00 a.m. to 7:30 p.m.
This satellite supports the inpatient
and outpatient areas in preparing and
dispensing chemotherapy. In addition,
one full-time pharmacist provides
clinical consultation to the oncology
service and one full-time pharmacist
provides clinical support to the Bone
Marrow Transplant Service.

Cancer Outreach/School
Re-entry Services
Participants: Nurse, Social
Worker, Child Life Therapist/Music
Therapist
A team of division members works to
build strong connections among the
hospital, parents/child, and each child’s
school. Staff is involved in identifying
hospital personnel as liaisons to
schools. Once identified, school staff
is provided with important information
and are encouraged to ask questions
which ultimately provides them with a
better level of comfort/understanding
while interfacing with the child and
family. Additionally, school mates are
given accurate information and are able
to ask questions to relieve anxieties
regarding cancer.

The Children’s Mercy Cancer Center Web site offers
patient/family education, as well as public education
regarding childhood cancer.
Please visit us at www.childrensmercy.org and select
“Cancer Center” from the Services/Departments menu.

Cancer Care Committee Board Members
Medical Staff Members

Andrews, Walter, MD
Burleson, Amy, DDS
Cooley, Linda, MD
Covitz-Hardy, Lynne, PhD
Dalal, Jignesh, MD
Emami, Abbas, MD
Gamis, Alan, MD, MPH Chairman
Gyves-Ray, Katherine, MD
Hetherington, Maxine, MD Assistant Chairman
Holcomb, G. Whit, MD
Hornig, Gregory, MD
Huseman, Carolyn, MD
Lewing, Karen, MD
Manalang, Michelle, MD
Massey, Vickie, MD
Morello, Frank, MD
Nicklaus, Pam, MD
Peters, Charlie, MD
Sharma, Mukta, MD
Shore, Richard, MD
Smith, Courtney, Pharm. D.
Snyder, Charles, MD
Woods, Gerald, MD
Zwick, David, MD

Surgery
Dentistry
Cytogenetics
Developmental Medicine
Hematology/Oncology
Hematology/Oncology
Hematology/Oncology
Radiology
Hematology/Oncology
Surgery
Neurosurgery
Endocrinology
Hematology/Oncology
Hematology/Oncology
Radiation/Oncology
Radiology
Otorhinolaryngology
Hematology/Oncology
Hematology/Oncology
Hematology/Oncology
Pharmacy / BMT		
Surgery-ACOS Liaison
Hematology/Oncology
Pathology

Non-Physician Members
Baer, Phyllis, RN
Bartholomew, Joy, RN, FNP, CPON
Brown, Pat, MS, TLMFT
Burns, Susan, RN, CPON
Corse, Cindy, CTR
Devorin, Barb, RN, CPNP
Fournier, Julie, RN, CPON
Green, Nancy, Sr. CNS
Haynes, Cindy, Chaplain
Hicks, Julie, APRN, BC
Hutto, CJ, RN, CPON
Jones, Ronald, PA-C
Klockau, Chris, RPh, BCOP
Laurence, Kris, CCRP
Marcus, Bette, RN, CPON
Mick, Kathy, RN, CPON
Ryan, Robin, CCRP
Seal, Annie, C.L.S.
Stamm, Susan, RN, MSN, PNP
Stegenga, Kristin, RN, PCNS, CPON
Walter, Christy, CCRP, LPN

Hematology/Oncology
Hematology/Oncology
Hematology/Oncology
Hematology/Oncology
Cancer Registry
Neurosurgery
Hematology/Oncology
Nutrition
Chaplaincy Services
Hematology/Oncology
Senior Director Allied Health
Hematology/Oncology
Pharmacy
Hematology/Oncology
Hematology/Oncology
Education
Hematology/Oncology
Child Life
Hematology/Oncology
Hematology/Oncology
Hematology/Oncology
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...tumors of the central nervous system and leukemia
were the most frequently occurring diagnoses at
Children’s Mercy Hospital in 2004.
Cancer registrations begin with
the identification of patients who
have been diagnosed or treated for
malignancies, or other certain benign
/ borderline conditions, at Children’s
Mercy Hospital (CMH) or clinics. The
Cancer Registry is operated under
the guidance of the Cancer Care
Committee and maintains the data
standard requirements of the American
College of Surgeons Commission on
Cancer (CoC) and the State of Missouri.
During 2004, 145 new cases were
added to the Cancer Registry, which
is the highest yearly total of patient
registration at CMH. From January
1990 until December 2004, the Cancer
Registry has recorded a total of 1,384
patients.
The following specifics are included
in the fundamental data collection:
1) Occurrence of cancer (incidence);
2) Types of cancer (site, morphology,
and behavior);
3) Extent of disease at time of 		
diagnosis (stage);
4) Kinds of treatment received by the
patients ; and
5) Outcomes of treatment (survival).
These data elements are retrieved
(abstracted) stored, and analyzed
under strict standards of patient
confidentiality. The Cancer Registry
continues to monitor patients annually
throughout their lifetimes. The data
from the annual follow-up identifies
additional treatment methods,
progression or remission of disease,
and the vital status of patients.
Medical staff at CMH have access
to survival data, as well as other
valuable information concerning patient
diagnosis and therapeutic efforts. This
information contributes to assessing the
care of the cancer patient.

Cancer Registry

As seen in recent years, tumors
of the central nervous system and
leukemia were the most frequently
occurring diagnoses at Children’s
Mercy Hospital in 2004. There were
39 central nervous system tumors
and 35 leukemia patients diagnosed
(see Figure 1). Patients included in
the registry are divided by class of
case category, which indicates where
the cancer was initially diagnosed
(see Figure 2). The analytic patients
are those eligible for inclusion in the
registry’s statistical reports of treatment
efficacy and survival. During 2004, 96
analytic patients (class of case 1) were
diagnosed at CMH, 28 patients came
to CMH for treatment after diagnosis
elsewhere (class of case 2). The nonanalytic patients are those in class of
case 3 category and also those with
reportable conditions included in the
registry by recommendation of the
Cancer Care Committee.
Thirty-seven cancer related deaths
were reported in 2004; 10 were
diagnosed during that year. Leukemia
and tumors of the central nervous
system represented the most frequent
diagnoses in this group (see Figure 3).

Cancer Registry
CHILDREN’S MERCY HOSPITAL
CANCER REGISTRY
2004 FREQUENCY OF DIAGNOSIS
FIGURE 1
Central Nervous System
Astrocytoma
Glioma
Medulloblastoma
Atypical Teratoid
		 Rhabdoid Tumor
Ependymoma
Germinoma
Primitive Neuroectodermal
		 Tumor
Benign/Borderline Tumors

39
9
6
4

Leukemia
ALL
AML
Juvenile myelomonocytic

35
22
11
2

(25%)

Lymphoma
Non-Hodgkin’s
Hodgkin’s

12
8
4

(8%)

Neuroblastoma

12

(8%)

Osteosarcoma

6

(4%)

Wilms Tumor

4

(3%)

Ewing’s Sarcoma (EFT)

3

(2%)

Retinoblastoma

3

(2%)

31
2
2
1

(21%)

Other
Rhabdomyosarcoma
Mixed Germ Cell
Fibrosarcoma
Desmoplastic Small Round
		 Cell Tumor
Angiosarcoma
Undifferentiated Sarcoma
Alveolar Soft Part Sarcoma
Melanoma
Misc. Reportable Conditions

(27%)

Class 0 = 1
Diagnosed at CMH – received all of first course of treatment elsewhere.
Class 1 = 96
Diagnosed at CMH – received all or part of first course of treatment at CMH.

2
2
2

Class 2 = 28
Diagnosed elsewhere – received all or part of first course of treatment at CMH.

2
12

1
1
1
1
1
21

CLASS OF CASE
(ACOS-COC CLASSIFICATION)
AND REPORTABLE CONDITIONS
FIGURE 2

Class 3 = 1
Diagnosed elsewhere – received all of first course of treatment elsewhere.
Now at CMH with recurrence, disease progression, or subsequent treatment.
Reportable Conditions* = 19 (Benign / Borderline)
Included in the Registry due to location of tumor or because of its propensity
to recur.
*The Cancer Care Committee has approved the following conditions to be
included in the Registry. These conditions are collected in addition to the
histologic malignant behavior cases.
Borderline / Benign lesions of the Central Nervous System- 		
(Beginning 1/1/04 these conditions are required to be collected and
reported to the State of Missouri and are included in the analytic 		
numbers above.)
Mesoblastic nephroma
Tereatomas, regardless of locations.
Theca cell- granulose cell tumor
Lymphoproliferative Disease
Ganglioneuroma
Myeloproliferative Disease
Langerhan’s Cell Histiocytosis

2004 MORTALITY DATA
FIGURE 3
Leukemia		
		 AML
8
		 ALL
2
		 JMML
1

11

Central Nervous System		
		 Astrocytoma
4
		 PNET
2
		 Craniopharyngioma
1
		 Ependymoma
1
		 Glioma
1
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Neuroblastoma		

4

Osteosarcoma		

3

Ewing’s Sarcoma		

2

Lymphoma		

1

Malignant Rhabdoid of Liver

1

Fibrosarcoma		

1

Hepatocellular Carcinoma		

2

Malignant Langerhan’s Cell
Histiocytosis		

1

Desmoplastic Small Round Cell
Tumor		

1

Angiosarcoma		

1

A Five-Year comparison of
most frequently occurring diagnoses at
Children’s Mercy Hospital
FIGURE 4
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Total Diagnoses

Survivors

Ewing’s family of tumors
Five-Year Survival rate
CMH 1995 - 2004

Elapsed Time
Ewing’s / PNET
FIVE YEAR SURVIVAL DATA (10 YEAR PERIOD)
CHILDREN’S MERCY HOSPITAL
CHILDREN’S ONCOLOGY GROUP
			
(NATIONAL)
Number of Patients 		
21 		
62
Overall Survival (%) 		
72 		
60
EVENT FREE SURVIVAL (%) 		
60 		
58

The Ewing’s Sarcoma Family of Tumors
INTRODUCTION

Ewing’s sarcoma (ES), was first
described as a distinct malignancy by
James Ewing in 1921. Advances in
immunohistochemical, cytogenetic,
and molecular genetic techniques
however have provided evidence that
Ewing’s sarcoma in fact is one of
the several neoplastic diseases
that are believed to originate from
neuroectodermis and include
Primitive Neuro-Ectoermal Tumor
(PNET)/extraosseous ES (EES),
malignant small-cell tumor of the
thoracopulmonary region (Askin’s
tumor), paravertebral small-cell tumor,
atypical ES, and adult neuroblastoma.
Hence, the term “Ewing’s Sarcoma
Family of Tumors (EFT).
These neoplasms can develop in
almost any bone or soft tissue, but
are most common in the long and flat
bones of extremities and pelvis. It is
particularly less common in the spine,
hands, and feet. Patients typically
present with localized pain and swelling.
Overt metastatic disease is found in
approximately 25 percent of patients
at the time of diagnosis. Microscopic

metastases however, is presumably
present in virtually all patients. Close to
80 percent to 90 percent of patients
will relapse if treated with local therapy
alone (surgery and/or radiation therapy).

Consequently, systemic chemotherapy
for treatment of occult disease has
evolved as an essential component of
treatment.
Modern diagnostic methodologies
and introduction of multidisciplinary
approach to treatment guided by
cooperative clinical trials have resulted
in a marked improvement in survival of
EFT patients. According to reports by
Surveillance, Epidemiology, and End
Results (SEER) program of the National
Cancer Institute, the five-year survival
rates for these patients increased
from 36 percent to 56 percent for the
period of 1975 to 1994. Today, longterm survival in patients with favorable
prognostic features is expected to
approach 70 percent to 80 percent.

CLINICAL PRESENTATION

Primary sites – ES commonly arises in
the bones of the extremities and pelvis.
A small percentage of patients present
with ES in bones of spine, hands,
and feet. Approximately 25 percent
of patients have a soft tissue primary
lesion.
Signs and symptoms – Presenting
complaints are usually localized pain
or swelling of a few weeks or months
duration. Not infrequently, trauma is the
initiating event that calls attention to
the lesion. The pain intensifies rapidly
and may be aggravated by exercise.
A firm, tender, and fixed soft tissue
mass can sometimes be present as
well. Clinical findings are dictated by
the location of the tumor and may be
loss of a joint function in juxtaarticular
tumors, pleural effusion or direct lung
involvement in lesions of chest wall,
and back pain, weakness or loss of
bowel and/or bladder control that
follow the lesions of spine or sacrum.
Nearly 10 percent to 20 percent of
patients have signs or symptoms of
fever, anorexia, weight loss, fatigue, or
anemia at presentation.

Approximately 80 percent of patients
present with localized disease as
judged by current imaging technologies.
Subclinically systemic disease however,
is presumed to be present in nearly all
patients as evidenced by a high rate
of overt metastases in the absence
of systemic therapy. Patients with
primary pelvic tumors are more likely to
present with metastatic disease. Lung
and bone are the predominant sites
of metastases at the time of diagnosis
or relapse. Lungs are the first site of
distant spread in 70 percent to 80
percent of cases. Bone metastasis
most frequently involves the spine.
Metastases to lymph node, liver, and
brain are uncommon.

STAGING EVALUATION

currently under investigation.
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Tumor biopsy is planned after a careful
evaluation of the patient and the
imaging studies. The biopsy material
should contain a sufficient quantity of
tumor to allow multitudes of diagnostic
procedure required to arrive a correct
diagnosis, and separate the ESFTs from
a number of “small round blue cell
tumors”.
The diagnosis could be established by
CT guided core-needle biopsy, although
an open biopsy would be more optimal.
Fine needle aspiration biopsy of the
primary tumor is not acceptable,
but may be considered to sample
suspicious sites for metastatic disease.

A comprehensive evaluation is required
to ascertain the diagnosis and
the extent “stage” of the disease before
deciding on the appropriate treatment.
It requires the collaboration by various
specialties of oncology, radiology,
surgery, pathology to name a few.
Radiographic studies – A plain
radiograph often demonstrates a
“permeative” or “moth-eaten” lesion
that point to a series of minute
destructive lesions that become
confluent over time. As the tumor
expands, the periosteum is elevated
and produces the radiographic sign of
Codman’s triangle, also described in
patients with osteosarcoma. Repeated
periosteal reactions deposit layers
of bone in a classic “onion skin”
appearance. A CT scan can provide
a better view of the extent of cortical
destruction and soft tissue disease. An
MRI however, is the ideal tool to better
delineate the tumor size, local bone and
soft tissue extent, and the relationship
of the tumor to the surrounding vessels,
nerves, and organs. A chest CT and a
radionuclide bone scan is also essential
to look for pulmonary metastasis
to lungs or. The role of PET scan is

Karyotype: 47,XX,+10,
t(11;22)(q24;q12)
FISH using the DNA probe for the
EWSR1 gene, which is normally
located on chromosome 22 at
band q12:

a.

A metaphase cell shows the
EWRS1 probe is split by the
t(11;22). The normal red/
green signal is located on the
normal chromosome 22; the
red centromeric end of the
EWSR1 probe remains on the
derivative chromosome 22,
while the green telomeric end
of the EWSR1 probe moves to
the derivative chromosome 11.

b.

An interphase nucleus with the
same probe pattern as seen in
the metaphase cell.

...neoplasms can develop in almost any bone
		
or soft tissue, but are most common in the
long and flat bones of extremities and pelvis.

Osteosarcoma, primary lymphoma of
bone, malignant fibrous histiocytoma of
bone, acute leukemia, and metastasis,
particularly neuroblastoma may be
radiographically difficult to distinguish
from ES.
Likewise, extraosseous ES and PNET
must be differentiated from benign and
malignant tumors of soft tissue.

PROGNOSTIC FACTORS

Some of the clinical and biological
findings can be used to better define
the prognosis and determine the
intensity of treatment.

Bilateral Bone marrow aspiration
and biopsy is among the necessary
components of staging to rule out bone
marrow involvement and widespread
disease.
Differential diagnosis – A number
of benign and malignant conditions
should be in the differential diagnosis
of a suspected ES tumor. Clinical,
radiographic, and laboratory findings
in subacute osteomyelitis may
closely mimic those of ES. Among
nonmalignant bone lesions, eosinophilic
granuloma and giant cell tumor of
bone could exhibit destructive lesions
somewhat similar to ES.

Disease extent – Presence or absence
of metastasis is the key prognostic
factor in ES. As stated before, patients
who have metastatic disease at
diagnosis have the worst prognosis.
Data reported by cooperative groups
in the US and the Europe indicate a
five-year survival of as much as 70
percent and 10-year event-free survival
of approximately 50 percent in patient
who have no metastasis at diagnosis.
The five-year relapse-free survival rate
for patients with disseminated disease
at presentation is 20-25 percent.
Patients with bone and lung metastases
have significantly worse than those
with bone metastases alone, who in
turn, fared worse than those with lung
metastases only.
Tumor site and size – Patients with
small primary tumors of <100 mL, and
a wide resection margins frequently
do well. High LDH level indicates a
large tumor burden and a poorer
prognosis. Incomplete surgical resection
of anatomically challenging sites (e.g.
pelvis or spine), is associated with a
poor treatment outcome.
Response to therapy – Response
to initial or induction phase of

Some reports suggest a better
		 outcome for children younger
than 10 years of age.

chemotherapy is emerging as another
important factor that accurately predicts
the chance of survival rates.
Histology of the tumors in ESFT does
not seem to play a significant role in the
treatment results.
Age – Some reports suggest a better
outcome for children younger than 10
years of age. Several small clinical trials
have reported less favorable outcome
in adults with ES. It is believed that
a higher tumor burden, and a lack of
participation in national cooperative
treatment programs appear to
negatively impact the final outcome.
Molecular findings – Nonrandom
chromosomal translocations involving
the Ewing’s sarcoma (EWS) gene on
chromosome 22 is a characteristic
feature of EFT. These translocations
result in fusion of genes on different
chromosomes, that in turn encode
hybrid proteins active in carcinogenesis.
At least 18 different structural
possibilities for gene fusions have been
reported in these tumors. There are two
sources of variability: the EWS fusion
partner (e.g., FLI1, ERG, ETV1, E1A,
or FEV) and the breakpoint locations
within the genes. This molecular
heterogeneity may have some influence
on the prognosis of EFT [48-51]. As an
example, a better outcome is reported
for patients with localized tumors
expressing the most common chimeric
transcript (the so-called type I transcript
in which EWS exon 7 is fused to FLI1
exon 6, which is present in about 60
percent of cases) compared to other
fusion types [49,50].
Variability in the EWS fusion partner
(e.g., FLI1, ERG, ETV1, E1A, or FEV)
and the breakpoint locations within
the genes has resulted in a number
of structural possibilities which may
have some influence on the prognosis
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of EFT. An notable finding has been
the lower risk of metastasis in patients
with localized tumors expressing the
chimeric transcript (fusion of EWS
exon 7 to FLI1 exon 6). Several
genetic alterations on the other
hand are associated with a worse
prognosis. Deletion of the short arm of
chromosome 1p, homozygous deletion
of CDKN2A, and p53 mutations are
notable examples of such genetic
accidents.

Use of prognostic factors for
treatment stratification – Lack of
a uniform staging system for EFT has
limited our ability to stratify treatments
according to the disease stage and
expected treatment outcome. Almost all
currently available treatment protocols
are designed on the basis of presence
or absence of metastatic disease, which
represents the only uniformly accepted
staging system. Newer treatment
protocols are beginning to design the
treatment arms according to prognostic
variables such as specific genetic
translocations, preoperative response
to chemotherapy, and site and size of
tumor.

TREATMENT

The combination of surgery,
chemotherapy and radiotherapy forms
the backbone of treatment
protocols for Ewing’s
sarcoma. Prior to 1960s,
patients were treated by
surgery and radiotherapy
and long-lasting disease free
survival was quite poor. As
with other childhood cancers
benefiting from advances
in chemotherapy, we have
witnessed a dramatic improvement
in failure free survival of patients with
ESFT. During the past two decades,
Vincristine, cyclophosphamide, and
doxorubicin have been the chief
chemotherapeutic agents used in
treatment protocols. Ifosfamide and

Magnetic resonant
imaging (MRI)
demonstrates increased
signal intensity in the
right femoral head and
adjacent soft tissue in
a patient with Ewing
sarcoma.

etoposide are the latest drugs that
have shown efficacy in preliminary
trials and are being incorporated in the
chemotherapy regimens. Today, we
are witnessing the emergence of novel
molecular-targeted treatments that
are reshaping our approach to cancer
treatment. Ewing’s sarcoma patients
no doubt will benefit from these “smart
drugs.”

Intense technetium 99m
HDP uptake in the right
greater trochanter and
femoral head of the
same patient..

Current treatment protocols have in
common three stages of: 1) “induction”
period of multiagent chemotherapy,
2) “local control” by means of surgery
or radiotherapy, or both, and 3)
“continuation chemotherapy”. The
conventional duration of this “NeoAdjuvant” treatment has generally been
about 50 weeks.

INDUCTION THERAPY

The primary goals of this 12-14
week phase are eradication of the
microscopic spread of disease that are
assumed to be present in almost all
patients, and shrinkage of
the primary tumor and any
visible distant metastases,
if present. An extensive
evaluation is done at the
conclusion of this period
to determine the optimal
approach to be undertaken
for the control of the tumor.

Local Therapy

The choice of surgery or
radiation therapy, alone or in
combination, hinges on the
location and size of the tumor. A careful
assessment of the risks and benefits of
the appropriate options is carried out
and discussed with the patient and the
family. Amputation, surgical debulking
alone, or in combination with radiation
therapy are the common means of
management at this stage. Paramount
in this decision making process is the
best estimation of benefit obtained from
a given course of action versus risks

inherent in all of the techniques being
considered. A curative intent and the
best possible preservation of function
of the involved limb or organ are the
topmost priorities in consideration.
In recent years, surgery has taken a
leading role over radiation therapy in
situations where a total resection is
feasible in patients who have no overt
metastases. Equally important is the
opportunity to assess the degree of
tumor kill in response to the induction
treatment and has profound effect in
estimation of overall prognosis.

CONTINUATION THERAPY

Further chemotherapy is initiated as
soon as the patient has recovered
from the local control measure(s). The
total duration of treatment in our most
recent protocol is approximately 46 to
50 weeks. Last year, The Children’s
Oncology Group completed a clinical
trial comparing a 30-week intensified
treatment to the standard, 48 weeks
protocol arm. The results of this trial are
not available at this time.

OFF THERAPY

Once off therapy, a close follow up at
regular intervals must be established
to monitor for disease recurrence or
late effects of treatment. In addition
to routine physical examinations and
laboratory/radiographic evaluations,
education of the individual and the
family plays a central role in effective
off therapy evaluations following cancer
therapy.
While early side effects of cancer
treatment such as emesis, pain, and
infection are easy to recognize and
control, longer term complications
such as infertility, cardiac disease,
or secondary malignancies may
occur years or decades following the
treatment. A lifelong surveillance is
essential for early identification and
management of these complications.

...early side effects of cancer treatment 		
such as emesis, pain, and infection
are easy to recognize and control...
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Diagnostic and Treatment Support Services

Cytogenetics

Ewing’s sarcoma is a member of the
Ewing’s sarcoma family of tumors
(EWSFT). The EWSFT includes Ewing’s
sarcoma (EWS) of bone, extraosseous
Ewing’s of soft tissues (EOE), peripheral
primitive neuroectodermal tumors
(pPNET), and Askin’s tumor of the
chest wall. The tumors are thought to
arise from a pluripotent neural crest
(postganglionic parasympathetic)
cell. The EWSFT show a spectrum of
histologic differentiation, from EWS,
a tumor without evidence of neural
differentiation, to pPNET, a primitive
neural tumor lacking ganglion cell
differentiation and frank neuropil, but
possessing rosettes by light microscopy
and obvious neurites and dense core
granules by EM.
The EWSFT is characterized genetically
by rearrangement of the EWS gene,
which is located on chromosome 22 at
band q12, with several different genes
that belong to the ETS gene family.
The most common rearrangement,
t(11;22)(q24;q12), is found in ~95
percent of cases. This t(11;22)
creates a chimeric gene by fusion of
the 5’ portion of the EWS gene to
the 3’ sequences of the FLI1 gene at
chromosome 11q24. Other variant
translocations, t(21;22)(q22;q12),
t(7;22)(p22;q12), t(2;22)(q13;q12),
t(17;22)(q21;q12), occur in a small
percentage of tumors and in each,
there is fusion of the EWS gene with
one of the ETS family genes. The
EWS and ETS gene fusion proteins are
transcriptional activators, which affect
gene transcription and cell proliferation.
These gene products are tumorigenic in
mice.
EWS is often described as one
of the “small round cell tumors”
(SRCT). SRCT include neuroblastoma,
rhabdomyosarcoma, lymphoma,
leukemia, synovial sarcoma, and
others. The SRCT often have poor

differentiation and so can be difficult
to separate. Genetic analysis may be
the best way to differentiate between
these tumors by detection of one of
the reciprocal translocations, either by
cytogenetic analysis, fluorescence in
situ hybridization (FISH), or reversetranscriptase polymerase chain reaction
(rt-PCR).

Pathology

Ewing’s sarcomas (EWS) that originate
in the bone or in the soft tissue
have similar gross, microscopic and
molecular genetic features. They
are solid grey tumors that are not
encapsulated but
infiltrate and destroy
the surrounding
tissue with foci
of hemorrhage
and necrosis.
Microscopically,
Ewing’s tumor
is generally
composed of small
undifferentiated
blast-like cells with
indistinct nucleoli
arranged in sheets.
Tumors may, on
few occasions, be
composed of larger
cells with more
abundant cytoplasm
and prominent
nucleoli. The cells
are frequently rich
in glycogen, best
demonstrated with
Periodic Acid Schiff
(PAS) staining,
a feature which
is helpful in distinguishing Ewing’s
sarcoma from undifferentiated
neuroblastomas. Occasional Ewing’s
tumors have focal neural differentiation
as demonstrated by the presence
of neurofibrillary rosettes (i.e. socalled “Homer Wright” rosettes) that
further complicates reliable diagnosis

and distinction from neuroblastoma.
This limited expression of neural
differentiation with the shared genetic
translocation involving chromosome
number 11 and 22, serve as the basis
for unifying EWS with other bone and
soft tissue primitive neuroectodermal
tumors and led to the designation as
“EWS-PNET” family or class of tumors.
Aside from occasional rosettes, EWS
are so undifferentiated and lack
specific architectural arrangements
and cellular features that the
pathologist must perform a battery of
special immunohistochemical stains
on the tumor to make a reliable
distinction between Ewing’s sarcoma
and a number of other common
and rare pediatric malignant tumors
that share this undifferentiated or
so-called “primitive small round
blue cell” morphology with EWS.
Immunohistochemical staining for
CD99 (MIC2 gene product) is most
helpful in distinguishing EWS (+)
from neuroblastoma (-). Leukocyte
markers including CD45, T cell, B
cell, and Tdt are helpful to distinguish
EWS (-) from lymphomas and
leukemias (+). Markers of skeletal
muscle differentiation, myogenin and
MYOD1, are helpful in excluding poorly
differentiated rhabdomyosarcoma
(+) from EWS (-). EWS cells also
have a highly characteristic gene

rearrangement involving exchange
of DNA on chromosome number 11
and number 22 [t(11;22)(q24;q12)]
or less frequently on chromosome

number 21 and number 22
[t(21;22)(q22;q12)] that is not
shared by the aforementioned lookalike tumors. These translocations
can be demonstrated by conventional
chromosome karyotyping, fluorescent
in-situ hybridization, or by molecular
genetic techniques, and provides
additional diagnostic confirmation of
EWS-PNET tumors.

Radiology

The mission of the Department of
Radiology is to provide state-of-theart medical imaging services in a safe
and caring environment to patients,
families, and referring physicians.
Services are tailored to meet the
patient’s medical needs while treating
each child as a unique individual. The
Department of Radiology provides
computerized tomography (CT) including
the latest development in multi-detector
CT, Magnetic Resonance Imaging
(MRI), ultrasound, nuclear medicine,
conventional and fluoroscopic studies,
as well as, leading edge interventional
radiology procedures. The department
is staffed by fellowship trained, board
certified pediatric radiologists and
a dedicated group of technologists,
nurses, and clerical staff. Our mission
statement is taken very seriously and
guides our daily practice.

Radiation Therapy

Radiation therapy has been an
important part in the management
of Ewing’s sarcoma since it was first
described in 1921, although the role
has certainly evolved. With the use of
combined modality treatment, radiation
has been reserved for treating locally.
In many cases, surgery has eliminated
the need for radiation therapy, but in
some cases, it remains an important
part of the treatment plan. Better
imaging now helps to tailor fields more
precisely, and decrease long-term
side effects. The Kansas City Cancer
Centers has partnered with the Division
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The whole treatment team and the family
		
needs to be supportive of the child’s choices
regarding mobility and function.
of Hematology/Oncology to ensure each
pediatric patient is offered the most
effective treatment options available.

Rehabilitation Services

Rehabilitation Medicine focuses on
optimizing function. If a child has
undergone limb salvage procedure or
amputation due to Ewing’s sarcoma,
a major goal from a rehabilitation
perspective is returning the child to
activities which are normal for him.
The approach may require multiple
considerations, such as equipment
to aid mobility (such as a walker or
cane, or even a wheelchair), or a
prosthetic device, coupled with a
therapy program to train the child in the
use of that equipment. Often children
need multiple pieces of equipment,
for example, a cane for walking, and
a wheelchair for long distance or for
speed. Endurance may be impaired,
especially with a prolonged illness and
the impact of his or her treatment,
and therapy can additionally guide the
strengthening and progressive activity
needed to improve that.
Prosthetic devices for children with
amputation due to Ewing’s or other
malignant processes need to be
designed with some specialized
components. Specialized knee joints
and energy storing feet may enhance a
child’s abilities. Because body weight
and the residual limb size may fluctuate
during chemotherapy, adjustable
temporary sockets can be used for
longer times compared to other
amputations, to assure optimal fit and
function. Growth is also built into the
prosthetic limb so that adjustments can
be easily made.
If a child enjoyed sports before his
illness, every effort is taken to modify
the activity, or how the child approaches
the sport after treatment. Even with
limb salvage, some children enjoy using
a sports wheelchair for speed and

meaningful inclusion and competition.
The whole treatment team and the
family needs to be supportive of the
child’s choices regarding mobility and
function.

Molecular Genetics

Ewing’s sarcoma displays a
translocation resulting in the fusion
of the EWS gene, located at 22q12,
and a gene of the ETS family of
transcription factors. In 90-95 percent
of cases, a t(11;22)(q24;q12)
leads to the gene fusion EWS-FLI1.
Analysis of breakpoints indicates that
the rearrangements occur through
illegitimate recombination, suggesting
a random process, followed by a
selection for rearrangements producing
a functional fusion gene.

EWS, the gene involved in all ES
translocations, may fuse with several
different partners in various types
of sarcomas. EWS is a ubiquitously
expressed RNA-binding protein. The
N-terminal domain can function
as a strong transactivation domain
and their promoters are strongly
and broadly activated, leading to
unrestricted high-level expression of the
resulting fusion gene. The FLI1 gene
is a tightly regulated transcriptional
activator normally expressed in the
hematopoietic lineage. It is thought
to be involved in early hematopoietic,
vascular, and neuroectodermal
development in model organisms. In
model assays, EWS-FLI1 functions as a
stronger activator of transcription than
native FLI1. The transcriptional targets
of this fusion gene are unknown.
The differential diagnosis of ES/
PNET is broad and can include other
“small round cell” tumors such as
neuroblastoma, small cell carcinoma,
lymphoma, ERMS, ARMS, or DSRCT.
Many of these diagnoses mandate
quite different treatment protocols.
Molecular diagnostic RT-PCR assays
for the various EWS gene fusions are
helpful in sorting out the differential
diagnoses. An important consideration

in the detection of these fusions is
the structural heterogeneity. Up to 18
types of in-frame EWS-FLI1 chimeric
transcripts have been observed
(see figure below for most common
types). Each fusion protein contains
the transactivating amino-terminal
domain of EWS (exons 1-7) and the
DNA binding domain of FLI1 (encoded
by exon 9). Many laboratories use
an FLI1 exon 6 reverse primer along
with the EWS exon 7 forward primer,
which will pick up a fusion signal in
85 percent of cases of EWS-FLI1
gene rearrangements. In the minority
of negative cases, other primer
combinations can be used to detect the
rare fusion types.
The molecular heterogeneity is clinically
significant, since the different molecular
variants seem to affect EWS-FLI1
activity. Patients with localized tumors
at diagnosis showing the most common
fusion type (see in ~2/3 of cases)
have a better prognosis compared
with patients with other fusion types.
This may be due to the fact that the
common fusion encodes a functionally
weaker transactivator and is associated
with a lower proliferative rate, compared
to the other forms.

Source: Leonard, Debora (ed). Diagnostic Molecular Pathology,
first ed. Philadelphia: Saunders, 2003
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